GlassScriptPhysician profile
Bindu Balani
NPI 1063489243
$65,329.55
in general payments reported to CMS, 2019-2025
9 companies · $8,284 in 2025
The $8,284 reported for 2025 was more than what 92% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,825 · 2020: $7,106 · 2021: $5,401 · 2022: $7,613 · 2023: $14K · 2024: $15K · 2025: $8,284.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20K · Consulting Fee: $11K · Travel and Lodging: $5,128 · Food and Beverage: $1,789.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $19,680.00 |
| Consulting Fee | $10,787.37 |
| Travel and Lodging | $5,127.81 |
| Food and Beverage | $1,788.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $63,785.02 | 2019-2025 | Epclusa |
| Astrazeneca Uk Limited | $1,056.78 | 2023 | |
| Viiv Healthcare Company | $206.09 | 2019-2025 | |
| Abbvie INC. | $155.72 | 2021-2025 | Avycaz, Dalvance |
| Daiichi Sankyo INC. | $71.46 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $35.44 | 2020-2024 | Hyqvia |
| Grifols USA, LLC | $19.04 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bindu Balani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.